focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.75
Bid: 41.50
Ask: 42.00
Change: -1.45 (-3.36%)
Spread: 0.50 (1.205%)
Open: 42.75
High: 42.75
Low: 41.50
Prev. Close: 43.20
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Successful Completion of Fourth Dose Escalation

17 Jan 2023 07:00

RNS Number : 9050M
Avacta Group PLC
17 January 2023


17 January 2023


Avacta Group plc


("Avacta" or "the Group" or "the Company")


Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study


Positive safety profile of AVA6000 continues in the fourth cohort


Analysis of six tumour biopsies confirms the tumour targeting potential of pre|CISIONTM technology


Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumour biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumour tissue confirming the tumour targeting potential of the pre|CISIONTM technology.


AVA6000 continues to be well tolerated by patients in cohort 4 with a marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration. Typical toxicities include alopecia, myelosuppression, nausea, vomiting, mucositis and cardiotoxicity. Importantly, even at the highest dosing levels in cohort 4, equivalent to more than double the normal dose of doxorubicin, the typical drug-related cardiotoxicity of doxorubicin was not observed.


A number of tumour biopsies obtained from patients in different cohorts have also been analysed in order to confirm the release of the active chemotherapy, doxorubicin, in the tumour tissue. This analysis shows that AVA6000 targets the release of doxorubicin to the tumour tissue at therapeutic levels which are much higher than the levels being detected in the bloodstream at the same timepoint.


19 patients with a range of advanced and/or metastatic solid tumours enrolled across four cohorts, have been administered AVA6000 to date. On the basis of the very favourable safety profile of AVA6000 in the study to date, the Safety Data Monitoring Committee (SDMC) has recommended continuation to higher dose cohorts with the aim of identifying a maximum tolerated dose (MTD) necessary to inform the dosing levels for the phase 1b and future studies. The Company expects that it will complete these additional cohorts during the first half of 2023.


Dr Alastair Smith, Chief Executive Officer of Avacta Group plc commented:

"We're delighted with the very positive data emerging from the dose escalation study of our lead pre|CISIONTM tumour targeted therapy AVA6000. The very significant reduction in the usual toxicities, plus the observed release of doxorubicin at significant levels in the tumour tissue, show that the pre|CISIONTM platform has the potential to significantly improve the safety and tolerability of chemotherapies, and other drugs, by targeting their release to the tumour.


"This is extremely encouraging as we work towards realising our vision of "chemotherapy without side effects" to make a meaningful difference to cancer patients' lives.


"We are now in a position to proceed beyond the fourth cohort in the dose escalation study to even higher doses than originally anticipated, which is an unexpected and very positive development. The data being generated in the ALS-6000-101 study are providing detailed insights into the pre|CISIONTM platform which add significant value to the technology and confirm the potential of the pre|CISIONTM platform."





The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.


For further information from Avacta Group plc, please contact:


Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

Michael Vinegrad, Group Communications Director


Tel: +44 (0) 1904 21 7070

Stifel Nicolaus Europe Limited (Nomad and Broker)

Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares / William Palmer-Brown


Tel: +44 (0) 207 710 7600

FTI Consulting (Financial Media and IR)

Simon Conway / Alex Shaw / George Kendrick


Tel: +44(0) 203 727 1000

Zyme Communications (Trade and Regional Media)

Lily Jeffery


Tel: +44 (0)7891 477 378


About Avacta Group plc -


Avacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.


Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer® immunotherapies and pre||CISION™ tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programmes in the pipeline as well as several global research collaborations and licensing partnerships. Avacta's lead programme, AVA6000, is a preCISION™ tumour-targeted form of the established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in patients with locally advanced or metastatic selected solid tumours.


The Affimer® platform is an alternative to antibodies that has been designed to address many of the drawbacks of antibodies which, despite their shortcomings, currently dominate the immuno-diagnostics and immuno-therapeutics markets.


The pre|CISION™ tumour targeting platform can be used to modify a chemotherapy in order to selectively release the active drug in tumour tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre|CISION™ modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.


Avacta's Diagnostics Division develops and supplies a broad range of in-vitro diagnostic (IVD) solutions. The Division is growing rapidly through an M&A strategy to deliver a global scale IVD business providing market leading solutions for healthcare professionals and consumers to inform treatment and monitor health and well-being. In October 2022, Avacta acquired Launch Diagnostics which serves the hospital pathology laboratory market in the UK and Europe. Avacta Diagnostic's research and development centre in Wetherby, UK uses its proprietary Affimer® platform to differentiate immunodiagnostic products to provide marketing leading performance.


To register for news alerts by email go to




About AVA6000


AVA6000 is a novel form of doxorubicin that has been modified with Avacta's pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index. AVA6000 has been designed to limit cell penetration of the drug- and therefore its cell killing effect- until it is specifically activated by fibroblast activation protein α (FAP) which is in high concentration in many solid tumours compared with healthy tissues. The resulting reduced exposure of healthy tissues to free doxorubicin has the potential to significantly increase its therapeutic index by reducing the incidence of adverse effects, including cardiotoxicity and myelosuppression.


Anthracyclines such as doxorubicin, a generic chemotherapeutic agent, with a market size that is expected to grow to $1.38bn by 2024[1], are widely used as part of standard of care in several tumour types, but its use is limited by cumulative dose toxicity associated with cardiomyopathy.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Date   Source Headline
30th Apr 20247:01 amRNSFull Year Results
30th Apr 20247:00 amRNSBoard Change
26th Apr 20249:51 amRNSBlock listing Interim Return REPLACEMENT
26th Apr 20247:00 amRNSBlock Listing Six Monthly Return
23rd Apr 20249:43 amRNSBlock Listing Application to AIM
23rd Apr 20247:00 amRNSNotice of Results
22nd Apr 202412:14 pmRNSIssue of Equity and Total Voting Rights
9th Apr 20245:00 pmRNSAvacta Reports Data at the AACR Annual Meeting
8th Apr 20247:00 amRNSAVA6000 Abstract Release by AACR
28th Mar 20244:00 pmRNSInvestor Webinar
21st Mar 20247:00 amRNSUpdate on AVA6000 Phase 1a Clinical Trial Progress
18th Mar 20241:26 pmRNSResult of General Meeting
6th Mar 20247:00 amRNSAvacta Announces AVA6000 Poster at AACR
5th Mar 20247:00 amRNSResult of REX Retail Offer
29th Feb 20247:00 amRNSResult of Placing
28th Feb 20244:42 pmRNSProposed REX Retail Offer
28th Feb 20244:41 pmRNSProposed Fundraise to progress Therapeutics
16th Feb 20247:00 amRNSShare Incentive Plan/Issue of Equity
22nd Jan 202410:51 amRNSIssue of Equity and Total Voting Rights
19th Jan 20247:00 amRNSAppointment of Christina Coughlin
19th Dec 20237:00 amRNSAppointment of Chief Business Officer
13th Dec 20237:00 amRNSALS-6000-101 Phase 1a Study Data
4th Dec 20237:00 amRNSShareholder update to review AVA6000 Phase 1a data
27th Oct 20237:00 amRNSBlock Listing Six Monthly Return
23rd Oct 20231:30 pmRNSIssue of Equity and Total Voting Rights
18th Oct 20231:00 pmRNSBlock Listing Application to AIM
5th Oct 20237:00 amRNSAvacta to present at AACR-NCI-EORTC conference
28th Sep 20237:00 amRNSInterim Results for the Period Ending 30 June 2023
20th Sep 20232:00 pmRNSIssue of Equity and Total Voting Rights
20th Sep 20237:01 amRNSPeel Hunt Appointed as Joint Broker
20th Sep 20237:00 amRNSAppointment Dr.Christina Coughlin as a consultant
19th Sep 20237:00 amRNSSuccessful Completion of Sixth Dose Escalation
6th Sep 20237:00 amRNSNotice of Results
21st Jul 20233:00 pmRNSIssue of Equity and Total Voting Rights
28th Jun 202311:00 amRNSResult of Annual General Meeting
28th Jun 20237:00 amRNSAnnual General Meeting and Shareholder Event
21st Jun 20237:00 amRNSCompletion of Fifth Dose Escalation in AVA6000
19th Jun 20237:01 amRNSDirector Appointment
19th Jun 20237:00 amRNSStatement regarding market speculation
8th Jun 20237:00 amRNSAGM and Shareholder Event Detailed Agenda
5th Jun 20237:00 amRNSSecond Milestone in AffyXell Joint Venture
2nd Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSAvacta acquires Coris Bioconcept
27th Apr 20237:00 amRNSBlock Listing Six Monthly Return
27th Apr 20237:00 amRNSFirst Patient Dosed in the US in AVA6000 Phase 1
25th Apr 20237:00 amRNSPreliminary Results
21st Apr 20232:49 pmRNSIssue of Equity and Total Voting Rights
17th Apr 20237:00 amRNSAVA3996 data poster presented at AACR
6th Apr 20237:00 amRNS1st US Clinical Investigator AVA6000 Sites Opened
5th Apr 20237:00 amRNSFirst Patient Dosed in Fifth Cohort of AVA6000

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.